Localization and functional analyses of the MLC1 protein involved in megalencephalic leukoencephalopathy with
Oscar Teijido1, Albert Martínez, Michael Pusch
1Department of Biochemistry and Molecular Biology, Josep Samitier 1-5. Barcelona E-08028, Spain.
Abstract:
Mutations in the MLC1 gene are responsible for one form of the neurological disorder megalencephalic leukoencephalopathy with subcortical cysts (MLC). The disease is a type of vacuolating myelinopathy. The biochemical properties and the function of the MLC1 protein are unknown. To characterize MLC1, we generated polyclonal antibodies. The MLC1 protein was detected in the brain, assembled into higher molecular complexes, as assessed by assembly-dependent trafficking assays. In situ hybridization and immunohistochemistry were used to determine MLC1 localization within the adult mouse brain. MLC1 was expressed in neurons, detected preferentially in particular axonal tracts. This expression pattern correlates with the major phenotype observed in the disease. In addition, it was expressed in some astrocytes, concentrating in Bergmann glia, the astrocyte end-feet membranes adjacent to blood vessels and in astrocyte-astrocyte membrane contact regions. Other neuronal barriers, such as the ependyma and the pia mater, were also positive for MLC1 expression. MLC1 was detected in vivo and in heterologous systems at the plasma membrane. MLC mutations impaired folding, and the defect was corrected in vitro by addition of curcumin, a Ca(2+)-ATPase inhibitor. In summary, this study provides an explanation as to why mutations in MLC1 provoke the disease and points to a possible therapy for some patients.
Insights
Mutations in the MLC1 gene cause megalencephalic leukoencephalopathy with subcortical cysts (MLC). This study reveals MLC1 protein localization in the brain and suggests curcumin as a potential therapy for MLC disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a neurological disorder caused by mutations in the MLC1 gene.
- The function and biochemical properties of the MLC1 protein remain largely unknown.
- Understanding MLC1's role is crucial for deciphering MLC pathogenesis.
Purpose of the Study:
- To characterize the MLC1 protein's function and localization within the central nervous system.
- To investigate the molecular mechanisms underlying MLC disease caused by MLC1 mutations.
- To identify potential therapeutic strategies for MLC.
Main Methods:
- Generation of polyclonal antibodies against MLC1.
- Assembly-dependent trafficking assays to study protein complex formation.
- In situ hybridization and immunohistochemistry for precise localization in the adult mouse brain.
- In vivo and heterologous system expression studies to determine plasma membrane localization.
Main Results:
- MLC1 protein is detected in the brain, forming higher molecular complexes.
- MLC1 expression is localized in specific neuronal axonal tracts and certain astrocytes (Bergmann glia).
- MLC1 is present at the plasma membrane in vivo and in heterologous systems.
- MLC mutations lead to protein misfolding, which can be corrected in vitro by curcumin, a Ca(2+)-ATPase inhibitor.
Conclusions:
- This study elucidates the cellular localization and molecular behavior of MLC1, explaining the pathological consequences of its mutations in MLC.
- The findings highlight the potential of curcumin as a therapeutic agent for specific forms of MLC disease.
